Therapeutic Options for Patients With Multiple Myeloma in the Second Line and Beyond
This roundtable series reviews treatments in adult patients with multiple myeloma who have progressed on 1 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
Dosing Considerations for Selinexor in R/R Multiple Myeloma
April 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed considerations when using selinexor with various drug combinations in later-line multiple myeloma therapy. This is the second of 2 articles based on this event.
Physicians Discuss Recommended Therapies for R/R Multiple Myeloma
May 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.
Managing Adverse Events With Selinexor in R/R Multiple Myeloma
June 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
